Back to Global NewsPublished: 3 Mar 2026Download AppJoin TelegramWhy Atara's 7% Surge Could Signal a Turning Point for EBV Immunotherapy#Atara Biotherapeutics#tabelecleucel#FDA#PTLD#biotech#investment#immunotherapyDownload AppJoin CommunityShare Article